MAPT and Alzheimer disease: Notably, the injection of GLP-1 mimetics lowered the elevated total Tau levels in some AD animal studies (Li L. et al., 2012), but had no effect on soluble Tau in others (Li et al., 2010b; Chen et al., 2012).